Literature DB >> 7593466

Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults.

S Koskinen1, H Tölö, M Hirvonen, J Koistinen.   

Abstract

A follow-up study of anti-IgA antibodies in 159 healthy blood donors with severe deficiency of serum IgA (< 0.05 mg/L) and in 45 donors with decreased serum IgA levels (0.05-799 mg/L), identified in 1971-1980, was carried out. Initially anti-IgA antibodies were determined by a hemagglutination (HA) method and two reexaminations were done in 1990-1992 by an enzyme immunoassay. The median follow-up period was 19 years, during which anti-IgA level was changed considerably in only four persons, increased in two, and high level antibodies (> 1/1000 by HA) appeared in two. In reexaminations anti-IgA antibodies were found in 30 (19%) subjects with severe IgA deficiency and the antibody levels remained relatively constant in those who had high and medium antibody levels. Anti-IgA antibodies were not found in subjects with decreased, but detectable serum IgA. Thus it seems that only those healthy adults who have severe IgA deficiency develop anti-IgA antibodies and their anti-IgA levels remain fairly constant. Of the 159 subjects with severe IgA deficiency, 66 had a history of IgA exposure, but no correlation to anti-IgA development was noted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593466     DOI: 10.1007/BF01541089

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  28 in total

1.  Anaphylactoid transfusion reactions associated with anti-IgA.

Authors:  G N Vyas; H A Perkins; H H Fudenberg
Journal:  Lancet       Date:  1968-08-10       Impact factor: 79.321

2.  Long-term persistence of selective IgA deficiency in healthy adults.

Authors:  S Koskinen; H Tölö; M Hirvonen; J Koistinen
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

3.  A sensitive enzyme immunoassay for the measurement of low concentrations of IgA.

Authors:  M Hirvonen; S Koskinen; H Tölö
Journal:  J Immunol Methods       Date:  1993-07-06       Impact factor: 2.303

4.  Anti-IgA in selective IgA deficiency. In vitro effects and Ig subclass pattern of human anti-IgA.

Authors:  L Hammarström; M A Persson; C I Smith
Journal:  Scand J Immunol       Date:  1983-12       Impact factor: 3.487

5.  Anti-IgA-mediated transfusion reactions in Canada.

Authors:  C Laschinger; F A Shepherd; D H Naylor
Journal:  Can Med Assoc J       Date:  1984-01-15       Impact factor: 8.262

6.  Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.

Authors:  C Cunningham-Rundles; Z Zhou; S Mankarious; S Courter
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

7.  Anti-IgA antibodies in pregnancy.

Authors:  R E Petty; D D Sherry; J Johannson
Journal:  N Engl J Med       Date:  1985-12-26       Impact factor: 91.245

8.  Human antibodies to human IgA globulins.

Authors:  H H Fudenberg; E R Gold; G N Vyas; M R Mackenzie
Journal:  Immunochemistry       Date:  1968-03

9.  Normal human sera contain antibodies directed at Fab of IgA.

Authors:  S Jackson; R I Montgomery; J Mestecky; C Czerkinsky
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

10.  An enzyme immunoassay for the determination of anti-IgA antibodies using polyclonal human IgA.

Authors:  S Koskinen; M Hirvonen; H Tölö
Journal:  J Immunol Methods       Date:  1995-02-13       Impact factor: 2.303

View more
  2 in total

1.  Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy.

Authors:  U Sundin; S Nava; L Hammarström
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

2.  Detection of anti-IgA antibodies using the particle gel immunoassay: a rapid test for increased patient safety.

Authors:  Simona Oltean; Andreea Epure; Karin Lindström; Cecilia Pardi
Journal:  Blood Transfus       Date:  2014-01-16       Impact factor: 3.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.